爱康国宾捅了“马蜂窝”

Core Viewpoint - The case of lawyer Zhang Xiaoling, who was diagnosed with late-stage kidney cancer after ten years of health check-ups at Aikang Guobin, raises serious concerns about the reliability of health check services in China, particularly regarding misdiagnosis and oversight in the industry [1][4][6]. Company Summary - Aikang Guobin has been a leading player in the health check industry, serving 1.483 million clients in Beijing alone from April 1, 2024, to March 31, 2025 [4]. - The company has faced increasing scrutiny and public backlash over allegations of "fake health checks" and misdiagnosis, with Zhang Xiaoling's case being particularly emblematic of these issues [4][6]. - Aikang Guobin's CEO, Zhang Ligang, previously criticized the industry for similar issues, which now seem to reflect back on his own company [4][8]. - The company has issued statements claiming that cancer detection is limited by time and equipment, and has denied any misdiagnosis or oversight [6][11]. Industry Summary - The health check industry is under intense scrutiny, with public trust eroding due to repeated allegations of misdiagnosis and oversight [5][10]. - Historical parallels are drawn to the infant formula scandal, emphasizing the need for accountability and quality assurance in health services [5]. - Complaints against Aikang Guobin have surged, with over 1,200 complaints reported on consumer platforms, indicating widespread dissatisfaction with service quality [8][9]. - The industry faces challenges related to quality control, with many institutions lacking proper medical testing standards and protocols, leading to potential health risks for consumers [20][22]. - The need for industry self-regulation and improved consumer education is highlighted, as many consumers are unaware of the limitations of certain health indicators used in screenings [21][23].